no worries. Maybe an old game, but gotta' admit, there are new players.
Step back from minute to minute action and look at larger steady upward trend. I think the new leadership is being viewed as *very* positive.
Admittedly, still need to shake off the old outdated "CRIS is just a pre-clinical" biopharma. See this as a market inefficiency and buying opportunity.
I do feel that since March 2013 when Ali was hired as COO, things have turned around at CRIS. Management has been upgraded *significantly* and Passeri seems to have been marginalized - just read the transcript of the Oct. 3, 2013 meeting. He was forced to speak last and all of his ho-hum commentary was immediately followed by COO A. Fattaey commentary. The writing is on the wall for the old guard.
I completely understand the dour predictions from all of the long time CRIS investors - I'd be gloomy also if I had to watch Passeri et al. mismanage the program over the last decade.
I can see light at the end of the tunnel.
Sentiment: Strong Buy